Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab, SBRT, and Chemotherapy in Luminal Breast Cancer
NCT06402435Phase 2Recruiting
- Sponsor
- Hubei Cancer Hospital
- Start
- Nov 2024
- Primary completion
- Aug 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in breast cancer, sponsored by Hubei Cancer Hospital. Started Nov 2024; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06402435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06402435.